View:
Download DOC
Download PDF
Download XLS
6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

Date of Report: June 29, 2023

Commission File Number: 001-36891

 

 

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

 

 

8, rue de la Croix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F  ☒    Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

General Meeting

Cellectis S.A. (the “Company”) held its Combined Ordinary and Extraordinary General Meeting (the “Meeting”) on June 27, 2023. Filed as Exhibits 99.1 and 99.2 hereto are the press release and the voting results for the Meeting, respectively.

Board of Directors Update

On June 27, 2023, Mrs. Cécile Chartier has been appointed as director of the Company’s board of director. The terms of office of Mr. Hervé Hoppenot and Mrs. Annick Schwebig ended just after the June 27, 2023 Meeting.

EXHIBIT INDEX

 

Exhibit   

Title

99.1    Press Release, dated June 28, 2023

99.2

   

Voting Results for the Combined Ordinary and Extraordinary General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

CELLECTIS S.A.

(Registrant)

June 29, 2023     By:  

/s/ André Choulika

      André Choulika
      Chief Executive Officer
EX-99.1

Exhibit 99.1

 

LOGO

PRESS RELEASE

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

June 28, 2023 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.

The detailed results of the vote and the resolutions are available on the company’s website: https://www.cellectis.com/en/investors/general-meetings/

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit our website www.cellectis.com

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube

For further information on Cellectis, please contact:

Media contact:    

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Investor Relation contact:    

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 

EX-99.2

Exhibit 99.2

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Ordinary Resolutions

 

NB

    Resolution      Result      For    

 

Against

     Vote withhold      Total votes      Shares
represented
by the
votes cast		      Percentage of the
share capital
represented by the
votes cast		     Out of vote
voting
rights		      Null voting
rights		      Quorum  
   Votes      %     Votes      %     Votes      %  

1

      Approval of the annual financial statements for the financial year ended December 31, 2022  
     1        Carried        44 957 162        99.48 %      233 303        0.52 %      27 732        —          45 190 465        40 379 160        72.645 %      0        0        72.645 % 

2

      Approval of the consolidated financial statements for the financial year ended December 31, 2022  
     2        Carried        44 957 137        99.48 %      233 303        0.52 %      27 757        —          45 190 440        40 379 160        72.645 %      0        0        72.645 % 

3

      Appropriation of results for the financial year ended December 31, 2022  
     3        Carried        44 926 569        99.41 %      265 543        0.59 %      26 085        —          45 192 112        40 379 160        72.645 %      0        0        72.645 % 

4

      Allocation of losses carried forward to the “share premium” account  
     4        Carried        44 957 932        99.48 %      233 808        0.52 %      26 457        —          45 191 740        40 379 160        72.645 %      0        0        72.645 % 

5

      Review of the agreements considered in articles L. 225-38 et seq. of the Commercial Code  
     5        Carried        38 406 039        99.39 %      233 938        0.61 %      12 433        —          38 639 977        36 692 873        66,013 %      6 565 787        0        72.645 % 

6

      Renewal of the appointment of Mr. Jean-Pierre Garnier  
     6        Carried        42 038 335        93.00 %      3 164 379        7.00 %      15 483        —          45 202 714        40 379 160        72.645 %      0        0        72.645 % 

 

1/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Ordinary Resolutions

 

NB

    Resolution      Result      For    

 

Against

     Vote withhold      Total votes      Shares
represented
by the
votes cast		      Percentage of the
share capital
represented by the
votes cast		     Out of vote
voting
rights		      Null voting
rights		      Quorum  
   Votes      %     Votes      %     Votes      %  

7

      Renewal of the appointment of Mr. Laurent Arthaud  
     7        Carried        43 046 342        95.23 %      2 156 396        4.77 %      15 459        —          45 202 738        40 379 160        72.645 %      0        0        72.645 % 

8

      Renewal of the appointment of Mr. Pierre Bastid  
     8        Carried        40 673 751        92.94 %      3 091 670        7.06 %      15 483        —          43 765 421        38 941 867        70.059 %      1 437 293        0        71.919 % 

9

      Renewal of the appointment of Mr. Rainer Boehm  
     9        Carried        42 089 019        93.11 %      3 113 719        6.89 %      15 459        —          45 202 738        40 379 160        72.645 %      0        0        72.645 % 

10

      Appointment of a new director (Mrs Cecile Chartier)  
     10        Carried        44 937 320        99.41 %      268 730        0.59 %      12 147        —          45 206 050        40 379 160        72.645 %      0        0        72.645 % 

11

      Authorization to the Board of Directors to buy back shares of the Company  
     11        Carried        44 678 742        98.84 %      526 086        1.16 %      13 369        —          45 204 828        40 379 160        72.645 %      0        0        72.645 % 

 

2/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Extraordinary Resolutions

 

NB

    Resolution      Result      For    

 

Against

     Vote withhold      Total votes      Shares
represented
by the
votes cast		      Percentage of the
share capital
represented by the
votes cast		     Out of vote
voting
rights		      Null voting
rights		      Quorum  
   Votes      %     Votes      %     Votes      %  

12

      Authorization to be granted to the Board of Directors to reduce the share capital by cancelling shares under the authorization to buy back its own shares  
     12        Carried        44 880 463        99.28 %      324 279        0.72 %      13 455        —          45 204 742        40 379 160        72.645 %      0        0        72.645 % 

13

      Amendment of the age limit applicable to the chairman of the Board of Directors – subsequent amendment of the articles of association  
     13        Carried        38 295 611        84.72 %      6 907 819        15.28 %      14 767        —          45 203 430        40 379 160        72.645 %      0        0        72.645 % 

14

     

 Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation
of shareholders’ preferential subscription rights in favor of the European Investment Bank (EIB) or of other entities that may succeed EIB, according to
any finance agreement entered or be entered with EIB		  
 
 
     14        Carried        44 812 227        99.13 %      393 537        0.87 %      12 433        —          45 205 764        40 379 160        72.645 %      0        0        72.645 % 

15

     

 Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation
of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (investors with experience in the
health or biotech sector)		  
 
 
     15        Carried        44 588 540        98.63 %      617 502        1.37 %      12 155        —          45 206 042        40 379 160        72.645 %      0        0        72.645 % 

16

     


 Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation
of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (e.g. credit institution, investment
services provider or member of an investment pool guaranteeing the completion of the issue in question), including, as the case may, within the
framework of an equity financing program known as “At-the-market” or “ATM”		  
 
 
 
     16        Carried        44 570 910        98.60 %      635 132        1.40 %      12 155        —          45 206 042        40 379 160        72.645 %      0        0        72.645 % 

17

     

 Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities, with
cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (industrial companies,
institutions or entities active in the health or biotechnology sector)		  
 
 
     17        Carried        44 602 515        98.66 %      603 527        1.34 %      12 155        —          45 206 042        40 379 160        72.645 %      0        0        72.645 % 

 

3/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Extraordinary Resolutions

 

NB

    Resolution      Result      For    

 

Against

     Vote withhold      Total votes      Shares
represented
by the
votes cast		      Percentage of the
share capital
represented by the
votes cast		     Out of vote
voting
rights		      Null voting
rights		      Quorum  
   Votes      %     Votes      %     Votes      %  

18

     

 Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities with
cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics in the framework of
an equity or bond financing agreement		  
 
 
     18        Carried        44 602 475        98.66 %      603 567        1.34 %      12 155        —          45 206 042        40 379 160        72.645 %      0        0        72.645 % 

19

     

 Delegation of authority to be granted to the Board of Directors to decide on the issuance of ordinary shares to be issued immediately or in the future
by the Company, with cancellation of the shareholders’ preferential subscription rights, to the benefit of a category of persons meeting specified
characteristics within the framework of an equity financing program on the American market known as “At-the-market” or “ATM”		  
 
 
     19        Carried        44 602 475        98.66 %      603 567        1.34 %      12 155        —          45 206 042        40 379 160        72.645 %      0        0        72.645 % 

20

     
 Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities,
with the shareholders’ preferential subscription rights maintained		  
 
     20        Carried        44 869 970        99.26 %      336 332        0.74 %      11 895        —          45 206 302        40 379 160        72.645 %      0        0        72.645 % 

21

     

 Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities,
with cancellation of shareholders’ preferential subscription rights, by way of a public offering (other than the offerings referred to in paragraph 1 of
Article L. 411-2 of the French Monetary and Financial Code)		  
 
 
     21        Carried        44 556 890        98.56 %      649 412        1.44 %      11 895        —          45 206 302        40 379 160        72.645 %      0        0        72.645 % 

22

     

 Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities,
with cancellation of the shareholders’ preferential subscription rights in the context of an offer referred to in paragraph 1 of Article L. 411-2 of the
French Monetary and Financial Code		  
 
 
     22        Carried        44 602 475        98.66 %      603 827        1.34 %      11 895        —          45 206 302        40 379 160        72.645 %      0        0        72.645 % 

23

     
 Delegation to the Board of Directors to increase the number of shares to be issued in the event of a capital increase with or without preferential
subscription rights		  
 
     23        Carried        44 682 772        98.84 %      523 530        1.16 %      11 895        —          45 206 302        40 379 160        72.645 %      0        0        72.645 % 

 

4/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 27, 2023

VOTE RESULTS

Extraordinary Resolutions

 

NB

    Resolution      Result      For    

 

Against

     Vote withhold      Total votes      Shares
represented
by the
votes cast		      Percentage of the
share capital
represented by the
votes cast		     Out of vote
voting
rights		      Null voting
rights		      Quorum  
   Votes      %     Votes      %     Votes      %  

24

      Overall limitations on the amount of issues made under the Fifteenth resolution to the Twenty-third resolution aforementioned  
     24        Carried        44 957 035        99.45 %      248 989        0.55 %      12 173        —          45 206 024        40 379 160        72.645 %      0        0        72.645 % 

25

      Delegation of authority granted to the Board of Directors to increase the capital by incorporation of premiums, reserves, profits or other  
     25        Carried        44 949 687        99.43 %      256 337        0.57 %      12 173        —          45 206 024        40 379 160        72.645 %      0        0        72.645 % 

26

      Authorization to the Board of Directors to grant options to subscribe for or purchase shares of the Company  
     26        Carried        43 511 983        96.25 %      1 693 781        3.75 %      12 433        —          45 205 764        40 379 160        72.645 %      0        0        72.645 % 

27

      Authorization to the Board of Directors to proceed with the free allocation of existing and/or new ordinary shares  
     27        Carried        43 701 908        96.67 %      1 503 856        3.33 %      12 433        —          45 205 764        40 379 160        72.645 %      0        0        72.645 % 

28

      Overall limits on the amount of issues made under the above issues made under the Twenty-sixth and the Twenty-seventh resolution above  
     28        Carried        44 959 774        99.46 %      246 269        0.54 %      12 154        —          45 206 043        40 379 160        72.645 %      0        0        72.645 % 

29

     
 Delegation to the Board of Directors to proceed with an increase in the share capital, the subscription of which would be reserved for the members of a
company savings plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code		  
 
     29        Rejected        5 796 401        12.83 %      39 396 224        87.17 %      25 572        —          45 192 625        40 379 160        72.645 %      0        0        72.645 % 

 

5/5